Stocks Screeners Features Pricing
Sign In Get Started

Revvity Stock Analysis

NYSE: RVTY | Health Care | Health Care Equipment
Price $101.07 +$0.68 (+0.68%)
P/E Ratio 46.5 TTM
52-Week Range
Low $81 High $118
Market Cap $11.44B USD
ROE 3.3% Annual

Market data as of Jun 3, 2026 · Financials as of Dec 2025

Published May 24, 2026 · Updated May 27, 2026

How has Revvity (RVTY) been performing? Here's a data-driven look at its financials, valuation, and shareholder returns.

Revenue Trend

Revvity's top line grew 3.7% to $2.86B in FY2025, compared to $2.76B in FY2024.

Over the past 10 years, revenue has grown at just 3.1% annually — from $2.10B to $2.86B. That barely keeps up with inflation.

Revvity's $2.86B revenue base puts it in the smaller bracket among US health care companies.

Revenue Trend
Year Revenue YoY %
FY2025 $2.86B +3.7%
FY2024 $2.76B +0.2%
FY2023 $2.75B -16.9%
FY2022 $3.31B -13.5%
FY2021 $3.83B +1.2%

See Revvity's complete revenue history below

Revenue by Segment

Looking under the hood at Revvity's revenue mix for FY2025.

Product Revenue Mix (FY2025)
Segment Revenue % of Total
Life Sciences $1.43B 50.1%
Diagnostics $1.42B 49.9%

At 50.1% of total revenue, Life Sciences is by far Revvity's largest segment.

Notably, Life Sciences grew 14.1% YoY, taking its share to 50.1% of total revenue.

Geographically, Revvity's revenue is split across Other International (60%), United States (25%), China (9%), Germany (4%), and United Kingdom (3%).

Profitability Analysis

Net income for Revvity weakened to $241.7M in FY2025, 18.3% lower than the $295.8M posted in FY2024.

The net margin narrowed from 10.7% to 8.5%, suggesting rising cost pressures.

On a per-share basis, diluted earnings were $2.08 in FY2025 versus $2.41 in FY2024.

View Revvity's complete earnings and margin analysis

Dividends & Buybacks

In FY2025, Revvity distributed $0.29 per share in dividends (0.30% yield).

The dividend track record is notable: Revvity has maintained payouts for 10+ straight years.

With a 13.9% payout ratio, there's headroom for future dividend increases.

Revvity Shareholder Dividend Record
Year DPS Payout Ratio
FY2025 $0.29 13.9%
FY2024 $0.28 11.6%
FY2023 $0.28 Net loss — payout ratio not meaningful
FY2022 $0.28 6.2%
FY2021 $0.28 3.4%

On the buyback front, Revvity has spent $2.04B repurchasing shares over 11 years, reducing the float and boosting per-share metrics.

See how buybacks have impacted Revvity's share count over time

Revvity Debt & Liquidity

Key Balance Sheet Metrics (FY2025)
Metric Value
Cash & Short-term Investments $919.9M
Total Debt $3.66B
Shareholders' Equity $7.25B
Total Assets $12.17B
Debt-to-Equity Ratio 0.51x
Current Ratio 1.68x
Interest Coverage 3.9x
Free Cash Flow (TTM) $508.3M

The numbers look healthy: Revvity carries $3.66B in debt against $919.9M in cash, with a comfortable D/E ratio of 0.51x.

The current ratio of 1.68x indicates Revvity can comfortably meet short-term obligations.

A 3.9x interest coverage ratio gives Revvity a moderate cushion above its debt service costs.

Strong free cash flow generation of $508.3M gives Revvity financial flexibility for capital allocation.

Explore Revvity's full balance sheet and cash flow analysis below

Revvity reported a headcount of 11,000 in FY2025, about $259.6K in revenue per employee.

Explore Revvity's headcount trend and workforce productivity

Is Revvity Fairly Valued?

Is Revvity stock overvalued or undervalued? Here's what our valuation models suggest.

Revvity shares are currently trading at $101.07.

The P/E Ratio approach puts Revvity's intrinsic value at $56, a 79.3% downside from the current market price.

We also calculate intrinsic value using the DCF and EPS Growth models. Sign up to see the full breakdown with fair value estimates.

Valuation Models
Model Est. Fair Value vs. Current Price
P/E Ratio $56 79.3% downside to fair value
DCF Upgrade Upgrade
EPS Growth Upgrade Upgrade

Key Takeaways

In summary, Revvity (RVTY) presents the following picture for fundamental analysts.

Revenue of $2.86B in FY2025, up 3.7% year-over-year.

Long-term revenue has been compounding at 3.1% annually over 10 years.

The company is profitable, with a net margin of 8.5% and net income of $241.7M.

Returned $853.6M to shareholders in FY2025 through dividends and/or buybacks.

Conservative balance sheet with a D/E ratio of 0.51x.

The P/E Ratio model implies 79.3% downside to fair value. The remaining 2 models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.

See the full picture: Revvity's interactive charts, valuation models, and financial trends are below.

Frequently Asked Questions

What is Revvity's annual revenue?
Revvity (RVTY) reported annual revenue of $2.86B in FY2025.
What is Revvity's net income?
Revvity (RVTY) posted net income of $241.7M in FY2025.
Does Revvity pay a dividend?
Yes, Revvity pays a regular dividend to shareholders.
What is the fair value of Revvity stock?
Based on the P/E ratio model, Revvity appears overvalued — trading at a 72% premium to its estimated fair value of $56.
What sector is Revvity in?
Revvity (RVTY) operates in the Health Care sector, specifically in the Health Care Equipment industry.

What does Revvity do?

Revvity provides instruments, reagents, software, and services for life sciences research and clinical diagnostics. Its Discovery & Analytical Solutions segment covers scientific imaging, detection, and environmental and industrial analytics, while its Diagnostics segment focuses on newborn and prenatal screening, infectious disease testing, and genomic workflows for oncology and immunodiagnostics.

Detailed Charts

Revvity Performance

2-year trend showing revenue, gross profit, and net profit

FY2024 – FY2025

Revvity's revenue grew 3.7% to $2.86B in FY2025, but net profit declined 18.3% to $241.68M — indicating margin compression.

Understanding Company Performance

Revenue is Revvity's total income from operations. Gross Profit is revenue minus cost of goods sold — the higher it is relative to revenue, the stronger the company's pricing power. Net Profit is the bottom line after all expenses, taxes, and interest. Consistent growth across all three signals a healthy, expanding business. Compare with peers in the same sector.

Is Revvity Profitable?

2-year trend showing gross, operating, and net profit margins

FY2024 – FY2025

Revvity's net profit margin of 8.5% in FY2025 reflects thin profitability, with operating margin at 12.5% and gross margin at 53.1%.

Understanding Profitability Margins

Gross Profit Margin (GPM) shows what percentage of Revvity's revenue remains after direct production costs. Operating Profit Margin (OPM) factors in operating expenses like R&D and SG&A. Net Profit Margin (NPM) is the final profitability after all costs including interest and taxes. Stable or improving margins indicate pricing power and cost discipline.

Revvity Revenue & Earnings Growth

2-year trend showing revenue and diluted EPS

FY2024 – FY2025

Revvity's revenue grew 3.7% YoY in FY2025, but EPS declined 13.7%, indicating margin pressure.

Understanding Revenue & Earnings Growth

Revenue is Revvity's total income from operations — the top line. Diluted EPS (Earnings Per Share) is net income divided by all shares that could exist if stock options, RSUs, and convertibles were exercised. Revenue shows how fast the business is growing; EPS shows how much of that growth reaches shareholders after all costs and dilution. Healthy companies tend to grow both in tandem; when revenue grows but EPS shrinks, margins are compressing. Use our stock screener to compare growth profiles across companies.

Revvity Compound Annual Growth Rate (CAGR)

Metric 1-Year 5-Year 10-Year
Revenue +3.7% -5.5% +3.1%
Net Income -18.3% -19.8% +1.3%
EPS -13.7% -20.4% +1.0%
Share Price +11.3% -5.9% +6.7%

Revvity's 10-year revenue CAGR of 3.1% reflects slow growth, though EPS CAGR of 1.0% trails revenue, suggesting rising costs eating into profits. The share price has compounded at 6.7% annually over a comparable period, outpacing fundamentals — suggesting the market is pricing in higher future growth.

Revvity Quarterly Performance

Quarterly revenue and net income with a weekly share-price overlay

Upgrade to see the full 5 years (20 quarters) of quarterly data.

FY2025 – FY2026

How to Read Quarterly Performance

Quarterly revenue and net income are Revvity's most recent three-month results. Each bar shows net income nested inside revenue, since profit is the slice of revenue left after all costs; the taller the green portion relative to the blue, the more of each sales dollar reached the bottom line. A bar below zero is a quarterly loss.

For a long-term view, compare each quarter with the same quarter a year earlier (year-over-year), not with the previous quarter — sequential change is mostly seasonality (for many businesses the holiday quarter is always the biggest). Then watch the trend across several years: is year-over-year revenue growth accelerating or fading; is net income growing at least as fast as revenue (expanding vs compressing margins)? One quarter is noise — the multi-quarter trend is the signal.

Revvity Share Price vs Book Value

Revvity (RVTY) share price vs book value per share — FY2016 – FY2025

Understanding Share Price vs Book Value

Share Price is what the market pays per share of Revvity. Book Value per Share (BVPS) is the company's net equity divided by diluted shares — the accounting floor if the company were liquidated today. When price tracks close to book value the market sees the company as a steady asset; when price runs far above book the market is paying up for expected future earnings. For banks, book value is the primary valuation anchor; for most other companies it's one signal among many.

Unlock Valuation Analysis

Get fair value estimates from multiple valuation models and see whether a stock is undervalued or overvalued.

  • Multi-model fair value estimates (P/E, DCF, EPS Growth)
  • Undervalued/overvalued assessment with upside potential
  • Compare fair values across methodologies

Revvity Free Cash Flow

2-year trend — cash generated after reinvestment

FY2024 – FY2025

Revvity's free cash flow of $508.26M in FY2025 represents a 17.8% FCF margin — healthy cash generation supporting dividends, buybacks, or debt reduction.

Understanding Free Cash Flow

Free Cash Flow (FCF) is Revvity's operating cash flow minus capital expenditure — the cash left over after maintaining and growing the business. Unlike net profit, FCF strips out non-cash items (depreciation, stock-based compensation) and includes actual cash spent on assets. Positive FCF means the company can pay dividends, buy back shares, reduce debt, or make acquisitions without raising capital. Consistently negative FCF signals the company is burning cash and may need external funding.

Revvity Financial Ratios

Balance sheet strength and debt servicing capacity

FY2024 – FY2025

Debt-to-Equity

0.51

▲ from 0.46

Current Ratio

1.68

▼ from 3.60

Interest Coverage

3.9x

▼ from 4.26

Revvity's a debt-to-equity ratio of 0.51, a current ratio of 1.68, interest coverage of 3.9x in FY2025 indicate a well-capitalized balance sheet with comfortable debt levels.

Understanding Financial Health

Debt-to-Equity (D/E) measures how much debt the company carries relative to shareholder equity — lower means less leverage risk. Current Ratio divides current assets by current liabilities — above 1.0 means the company can cover short-term obligations. Interest Coverage is operating income divided by interest expense — higher means the company earns well above its debt payments. Together these three metrics reveal whether a company can weather downturns without financial distress.

Revvity Shares Outstanding

Diluted share count per fiscal year — labels show year-over-year change

FY2024 – FY2025

Revvity's diluted shares decreased 7.8% YoY in FY2025, indicating shareholder-friendly buybacks.

Understanding Shares Outstanding

Diluted shares outstanding counts every share of Revvity that could exist if all stock options, RSUs, and convertibles were exercised. A shrinking count signals buybacks (returning cash to shareholders by reducing the denominator of EPS). A growing count signals dilution — usually from stock-based compensation, secondary offerings, or stock-funded acquisitions. Routine 1–2% growth is typical at large-cap tech companies that pay employees in equity; sustained growth above 5% warrants a look at the cause.

Unlock Full Analysis

Get the complete 10-year financial history with interactive charts and growth analysis.

Related Stocks